6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A clinical breakdown of AndroGel's FDA approval history, current compounding legal status under 503A and 503B pathways, label requirements, and safety considerations for compounded testosterone gel.
A detailed comparison of how the FDA and EMA regulate AndroGel (testosterone gel), including approval history, cardiovascular safety reviews, label restrictions, and post-market surveillance differences.
A clinical review of AndroGel (testosterone gel) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including cardiovascular events, polycythemia, transference risk, and regulatory label changes.
A full regulatory history of AndroGel (testosterone gel 1% and 1.62%), from its 2000 FDA approval through post-market safety updates, label changes, and ongoing surveillance requirements.
A complete timeline of AndroGel (testosterone gel 1%) FDA label revisions from 2020 through 2026, covering cardiovascular warnings, REMS modifications, transfer risk language, and post-market surveillance findings.
A clinical review of AndroGel's regulatory history, patent disputes, Paragraph IV litigation, FDA label changes, and cardiovascular safety controversies from approval through post-market surveillance.